Showing results (1541-1550 of 2,107) with videos related to

Sort By:
Pageof 211
CNS Drugs|November 28, 2025
Approved and Pipeline Pharmacological Interventions for Eating Disorders (2010-2025): 15 Years of Progress (or Lack Thereof)Drew Hirsch, Jace Reed, Aasim Naqvi, et al.
CNS Drugs|April 18, 2024
Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World DataHasan Çağın Lenk, Robert Løvsletten Smith, Kevin S O'Connell, et al.
CNS Drugs|January 8, 2024
Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with SchizophreniaXin Li, Chong Ye, Wanyi Zhang, et al.
CNS Drugs|June 27, 2015
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US PatientsBarbara H Johnson, Machaon M Bonafede, Crystal Watson
CNS Drugs|February 11, 2015
Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosisSheridan M Hoy
CNS Drugs|June 16, 2026
Managing Dermatologic Delusional Disorders: A US Psychodermatology Perspective for CliniciansAndrea Leung, John Koo
CNS Drugs|June 14, 2026
Cannabis and Cannabinoid-Related Suspected Adverse Drug Reactions: Global Patterns and Cross-National Analysis Based on VigiBase® DataPauline Schiro, Mónica Gálvez Pacoricona, Adèle Le Guilloux, et al.
CNS Drugs|July 15, 2026
Safety and Tolerability of Adjunctive Lumateperone for the Treatment of Major Depressive Disorder: A Pooled Analysis of Two Randomized Placebo-Controlled TrialsWillie R Earley, Suresh Durgam, Susan G Kozauer, et al.
CNS Drugs|December 8, 2017
Dispensability of Annual Laboratory Follow-Up After More than 2 Years of Valproic Acid Use: A Systematic ReviewRosanne W Meijboom, Koen P Grootens
CNS Drugs|July 30, 2026
PDE10A Inhibition in Schizophrenia: A Randomised, Placebo-Controlled Phase 2 Study of Alofropodect (CPL'36) in Patients Experiencing Acute SchizophreniaMaciej Wieczorek, Napoleon Waszkiewicz, Ewa Gromniak-Haniecka, et al.
Pageof 211